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Abstract
Background: Tuberculosis (TB) is a major infectious disease globally. Adequate and proper use of anti-TB drugs is
essential for TB control. This study aims to study China’s production capacity and sales situation of anti-TB drugs,
and to further discuss the potential for China to contribute to global TB control.
Methods: The production data of anti-TB drugs in China from 2011 to 2013 and the sales data from 2010 to 2014
were extracted from Ministry of Industry and Information Technology database of China and IMS Health database,
respectively. The number of drugs was standardized to the molecular level of the key components before calculating.
All data were described and analyzed by Microsoft Excel.
Results: First-line drugs were the majority in both sales (89.5 %) and production (92.3 %) of anti-TB drugs in China.
The production of rifampicin held the majority share in active pharmaceutical ingredients (APIs) and finished products,
whilst ethambutol and pyrazinamide were the top two sales in finished products. Fixed-dose combinations only held
small percentages in total production and sales weight, though a slight increase was observed. The production and
sales of streptomycin showed a tendency of decrease after 2012. The trends and proportion of different anti-TB drugs
were similar in production and sales, however, the production weight was much larger than that of sales, especially for
rifampicin and isoniazid.
Conclusions: First-line drugs were the predominant medicine produced and used in China. While the low production
and sales of the second-line TB drugs and FDCs rose concerns for the treatment of multiple drug resistant TB.
The redundant production amount, as well as the prompt influence of national policy on drug production and
sales, indicated the potential for China to better contribute to global TB control.
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Background
Tuberculosis (TB) remains a serious public health issue,
especially in the low- and middle-income countries.
Globally, there were an estimated 9.6 million new TB
cases and 1.5 million TB deaths in 2014 [1]. According
to the Global Tuberculosis Report 2015, effective diag-
nosis and treatment have saved 43 million lives between
2000 and 2014 [1]. However, the spread of multiple drug
resistant tuberculosis (MDR-TB) is undermining global
TB control. It was estimated that 3.3 % new cases and
20 % previously treated cases had MDR-TB; and in 2014,
nearly 190 000 cases died from MDR-TB [1]. Resistant
strains emerged mainly from the inadequate use of
TB drugs, use of low-quality drugs, poor TB program
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performance or lack of regulation [2]. The currently
recommended treatment for new cases of drug-sus-
ceptible TB is a six-month regimen of four first-line drugs:
isoniazid, rifampicin, ethambutol, and pyrazinamide.
While MDR-TB patients are eligible for second-line treat-
ment. To reduce this burden, treatment coverage gaps
must be addressed with adequate and quality supplies for
both first-line and second-line drugs.
As one of the 22 high TB burden countries, China has
made great progress by reducing 51 % of TB prevalence
and 79.5 % of mortality rate between 1990 and 2010,
achieving the TB control targets of the United Nation’s
Millennium Development Goals ahead of time [3]. This
could be attributed to the nationwide implementation of
the World Health Organization (WHO)-recommended
DOTS (directly observed treatment, short-course) strat-
egy since the 1990s. However, China still has the world
second highest burden of both TB and MDR-TB in
2014. It was estimated that the prevalence and incidence
of TB in China were 668 and 390 per 100 000 popula-
tion, respectively. Meanwhile, 5.7 % new TB cases and
26 % retreated cases were MDR-TB in China [1]. This
was mostly because of the inappropriate TB treatments
and treatment interruption, especially among patients
treated within the hospital system. TB treatment in
China is provided by CDC and hospitals. Hospitalization
for 100 % of MDR-TB patients in 2014 was reported in
China [4]. However, hospitals provide limited outpatient
follow-up of TB patients. A Chinese survey showed that
over 40 % of the MDR-TB patients did not complete
their last treatment course, among whom most were
treated within the hospitals [5]. The Chinese government
has taken many actions along with DOTS, such as the free
treatment policy and the use of anti-TB fixed-dose com-
bination (FDCs). Studies are needed to illustrate the effect
of policies and regulations for TB prevention in China,
and to provide new ideas for TB control. Until recently,
no study was seen to use the production and sales data to
evaluate this issue.
Understanding the production and sales status of anti-
TB drugs in China could also provide the world a glance
of how China might contribute to global TB control by
drug supply. The total market size of anti-TB drugs in
low-and middle-income countries is around $730 million.
Experts expected that the market for first-line drugs would
remain stable in the future while second-line drug market
would continue to expand with the improvement of detec-
tion technology for drug-resistant TB. Research on the
anti-TB drug market is needed, however, only few studies
were seen, especially in the perspective of the influence of
policies. Limited literatures on developing countries such
as Indian, Brazil, Philippines have revealed that different
countries face different patterns of the anti-TB drug mar-
ket [6–8]. Since many countries are still lack of TB
treatments, China is expected to contribute to global TB
control through drug supplies. However, no paper has dis-
cussed this possibility through quantitative production and
sales data. Only few market analyses were done many
years ago in China, focusing on limited drug types [9–11].
Thus, this study analyzed the recent production and
sales situation of anti-TB drugs to reveal the current
market of anti-TB drugs in China, and to discuss the
possible influence of policy and regulation. This research
could not only help value China’s production capacity
and medication situation towards TB treatment, but also




The production data of anti-TB drugs in China from
2011 to 2013 were from the Chinese government statistics
reported via the Ministry of Industry and Information
Technology (MIIT). MIIT requires certain manufacturing
enterprises to self-report their production data each year.
This data was the official national database of domestic
production in China. However, due to the limitation of
self-report, data on pyrazinamide active pharmaceutical
ingredients (APIs) production was missing and not
included in this analysis.
The original sales data of China’s anti-TB drugs during
2010 and 2014 were provided by IMS China from IMS
China Hospital Pharmaceutical Audit (IMS CHPA) data
source. IMS CHPA is the sampling statistics from over 9
000 hospitals in China and then zoom to the national
level reflecting the drug purchasing situation in hospitals
with 100 or more beds. IMS is a data source that in-
cludes sales data from various countries using the stand-
ard data collecting protocol. It has been used for
country comparisons in research articles [12].
Data analysis
Anti-TB drugs were classified into APIs and finished
drugs in this research. APIs were classified statistically in
the molecular level while finished drugs were not only
classified in the molecular level but also according to the
components of the specifications of preparation. The
classification of first-line and second-line anti-TB drugs
was also used during analysis. The main first-line drugs
studied in this research were rifampicin, isoniazid, pyra-
zinamide, ethambutol, and streptomycin.
SAS package was used to group the original data, and
to extract and unify the molecular level of the key com-
ponents. The production and sales weight of the drugs
were then calculated by using the specifications of
preparation and packing. All the key components were
summed into different types of sublists. Microsoft Excel
was used for analysis and description.
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Results
The production status of anti-TB drugs in China
After adding the available production weight of anti-TB
APIs during 2011 and 2013, we found that basic anti-TB
APIs – rifampicin (1 191 tons) and isoniazid (606 tons)
had the highest production, followed by sodium ami-
nosalicylate, ethambutol hydrochloride, capreomycin
sulfate and rifapentine (Fig. 1). Anti-TB APIs in China
were mainly first-line drugs, while the second-line
drug sodium aminosalicylate also showed a high pro-
duction of 269 tons between 2011 and 2013.
Finished drugs were classified into the molecular
level to analyze drug production status. The top five
production weight of anti-TB finished drugs in 2013
was rifampicin, ethambutol hydrochloride, pyrazina-
mide, isoniazid, and streptomycin sulfate, which were
all first-line drugs. The production weight of first-line
finished drugs takes up to 93, 92 and 92 % of the total
finished drugs in 2011, 2012 and 2013, respectively
(Fig. 2). The total trend of anti-TB finished drugs in
China was rather stable between 2011 and 2013. How-
ever, the production of streptomycin sulfate in 2013
was less than 50 % of that in 2012, which decreased
from 124 360 kg to 59 911 kg.
Though the production of anti-TB FDCs in China
was still quite small, an increasing trend was ob-
served between 2011 and 2013. The total production
weight of FDCs rose rapidly from 10 tons in the
year of 2011 to 60 tons in 2012 and reached 99 tons
by 2013. The number of total production pieces also
tremendously increased from 80 million in 2011 to
350 million in 2013.
The sales status of anti-TB drugs in China
The total top four sales of anti-TB drugs in China during
2010 and 2014 were ethambutol (263.75 tons), pyrazi-
namide (249.85 tons), rifampicin (155.59 tons), and
isoniazid (142.42 tons), which were far more than the
rest of anti-TB drugs. Except for streptomycin, the
sales weight of first-line drugs in the molecular level
all showed a tendency of increase with around 10 %
growth rate annually from 2010 to 2014 (Fig. 3). The
sales weight of streptomycin continuously declined
since 2012, from 1695 kg in 2012 to 1216 kg in 2014.
While for the sales weight of the second-line drugs,
they all rose annually expect for p-aminosalicylic acid.
In total, first-line anti-TB drugs accounted for nearly
90 % of the anti- TB finished drug market each year
(Table 1).
The sales of the drugs for initial pulmonary TB treat-
ment took up to 53, 56, 63, 67 and 71 % of all anti-TB
drugs, while the volume for retreated pulmonary tuber-
culosis accounted for 9, 9, 7, 6 and 4 % in the year of
2010, 2011, 2012, 2013 and 2014, respectively. The rest
proportion was for treating MDR-TB and those not
mentioned in China’s Standard for Diagnosis and Treat-
ment of Pulmonary Tuberculosis (2012 Edition).
In the past 5 years, sales of anti-TB drugs rose annu-
ally, especially for the single ingredient medicines. The
total sales volume of single ingredient medicines in-
creased 35.2 % between 2011 and 2014, and accounted
for 95.7 % of all anti-TB drugs in 2014. While the
percentage of sales volume for FDCs, though slightly
increased, only account for less than 2 % of the total




































rifampicin isoniazide sodium aminosalicylate
ethambutol hydrochloride capreomycin sulfate rifapentine
Fig. 1 The change of production weight of the main anti-TB APIs in China between 2011 and 2013. Due to the limitation of data collection, data
on pyrazinamide APIs production was missing and not included in this analysis. No data was found on sodium aminosalicylate in 2012
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Discussion
This study showed that the production and sales of the
first-line anti-TB drugs have been increasing despite
the falling TB prevalence in China; while for those that
were removed from the first-line drug list or not listed
as first-line drugs, the number has been fallen in both
production and sales. The low production and sales of
anti-TB FDCs and the second-line TB drugs rose concerns
for the proper and adequate treatment of MDR-TB.
The redundant production amount suggested a possi-
bility for China to contribute to global TB control
through drug supplies.
The result showed that the production of anti-TB
FDCs in China were increasing. The use of FDCs can
help to reduce incorrect medication, avoid improper
single-drug regimen and secondary drug resistance [13].
Not much attention was paid in this area before result-
ing in the rapid increase of MDR-TB cases. From 2008,
guidelines and pilot programs have been conducted by
the Chinese government responding to WHO’s call to
promote the use of FDCs in the TB treatment. As men-
tioned in the Supply and Management of Anti-TB Drugs
of Guidelines for Implementing the National Tuberculosis
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EMB PZA RFP INH PAS Pa PFT 1,321Th SM Others (CPM, RFB, CS)
Fig. 3 The change of sales weight of the main anti-TB drugs (molecular level) in China between 2010 and 2014. CPM, capreomycin; CS, cycloserine;
EMB, ethambutol; INH, isoniazid; Pa, pasiniazid; PAS, p-aminosalicylic acid; PZA, pyrazinamide; RFB, rifabutin; RFP, rifampicin; RFT, rifapentine; SM,
streptomycin; 1 321Th, protionamide
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popularization in areas with the necessary conditions
[14]. Since 2008, pilots on the use of anti-TB FDCs
have been launched in 11 provinces (autonomous re-
gions and municipalities). As the result of the impletion
of policies and guidelines, by the end of 2010, 10 % of
patients with pulmonary tuberculosis have used anti-
TB FDCs and 17 drug companies have been qualified
to manufacture anti-TB FDCs [15]. In accordance with
these changes, this study also illustrated the increase in
production of anti-TB FDCs in China after 2011. How-
ever, China is still in the early stage of using anti-TB
FDCs, with the small number of varieties and the low
proportion of sales.
This study showed that the production and sales of
first-line anti-TB drugs have been increasing despite
the falling prevalence. This might be related to the free
anti-TB drug treatments for new active pulmonary
tuberculosis cases and retreated smear positive pul-
monary tuberculosis patients offered by the Chinese
government [11]. The results also revealed that first-
line anti-TB drugs held absolute superiority, taking up
around 90 % of the production and sales of the domes-
tic anti-TB drug market. The recommended medicines
in Standard for Diagnosis and Treatment of Pulmonary
Tuberculosis (2012) for initial and retreated pulmonary
tuberculosis both include the combination of isoniazid,
rifampicin, pyrazinamide and ethambutol, which were
all on the top of our sales list. It can be inferred that
the sales market of anti-TB drugs in China is
matched with the medication regimens recommended
by guidebooks. With the standardization of treatment
and the free treatment policy, there should be no sur-
prise that the production and sales of first-line anti-
TB drugs have been increasing despite the falling
prevalence.
Though adequate first-line drugs can be provided
through the system, improper use of these drugs has in-
creased the prevalence of MDR-TB in China. According
to China’s National Survey of Drug-Resistant Tubercu-
losis in 2007, one in four TB patients treated in the
public health system were receiving first-line tuberculosis
drugs while they have the disease that is resistant to
first-line isoniazid or rifampin (or both) [5]. Addressing
MDR-TB in China requires more emphasis on second-
line anti-TB treatment. However, the low production
and sales of the second-line drugs rose concerns for the
treatment of MDR-TB. Second-line anti-TB drugs are
included in the WHO-recommended regimen for MDR-
TB treatment. Globally, around 90 % of detected MDR-
TB patients in 2014 had started second-line treatment.
Though China has reported 100 % hospitalization of
MDR-TB patients in 2014, the limited outpatient follow-
up of TB patients causes the incompletion of MDR-TB
treatment and the improper use of first-line drugs [5].
Relevant policies are needed in China to focus more on
this issue.
Our results indicated that national policies might have
the ability to provide prompt influence on anti-TB drugs.
Drugs that were removed from or not listed in the first–
line drug list have shown a fallen trend in both produc-
tion and sales. For example, due to the severe side-
effects and the high rates resistance in drug-resistant
TB, streptomycin was removed from the list of first-line
drugs and is no longer in the major treatment plans for
retreated patients in the treatment guidelines of WHO
and China [15–17]. As a result, a rapid decrease in the
production and sales of streptomycin has been noticed
since 2012. Another example is the relatively small
sales volume of rifapentine and rifabutin in China. Rifa-
pentine and rifabutin are both the first-line drugs rec-
ommended by WHO, however, they were both not
listed as main treatment drugs in China’s official guide-
lines. This again suggested the possible influence of na-
tional guidelines on the production and sales of anti-
TB drugs in China.
Although this study used currently the most accurate
and official data, the source of the data still face some
limitations. First, since the production data were self-
reported to the Chinese government by certain enter-
prises, the data might be misstated, omitted or merged.
Also, the production weight of finished products or
FDCs might include the weight of other partner drugs
or packaging. However, due to the stable standard require-
ments, the results should illustrate the actual tendency.
Since this data was the only governmental official data
and used for policymaking, the results should provide
enough information for further discussion. Besides, the
sales data from IMS CHPA only reflects the drugs sold in
hospitals with 100 or more beds. Though most patients
receive treatment from these hospitals, the data might be
smaller than the actual number, since medicines sold from
other places were not included.
Table 1 Total sales weight of first-line and second-line anti-TB drugs in China from 2010 to 2014 (Kg)
The total sales weight 2010 2011 2012 2013 2014
First-line drugs 123 931 141 158 172 034 188 051 194 446




89 % 89 % 89 % 90 % 90 %
Huang et al. Infectious Diseases of Poverty  (2016) 5:88 Page 5 of 6
Conclusion
This study showed the macro picture of the production
and sales situation of anti-TB drugs in China. Despite
the falling prevalence in China, with the standardization
of treatment and the free treatment policy, the produc-
tion and sales of first-line anti-TB drugs have been in-
creasing. The limited amount of second-line anti-TB
drugs and FDCs rose concerns for the adequate treat-
ment of MDR-TB, and should be noticed for future pol-
icymaking. Policies, guidelines, plans and standards from
the national government and WHO might place import-
ant influences on the production and sales of anti-TB
drugs, which in turn contribute to TB control and treat-
ment. Moreover, the redundant production amount also
illustrated the possibility for China to contribute to glo-
bal TB control through drug supplies.
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